Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07916350

A Study of the Safety and Effectiveness of a Compound Steep-Pulse Therapy Apparatus for Malignant Liver Tumors

Conditions: Malignant Liver Tumors

Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: NA
Enrollment: 181
Sponsor: REMD Medical Technology

Location: Nortion Medical Technology Co., Ltd Shanghai Shanghai Municipality

Summary

This prospective, multicenter, randomized, parallel-group, open-label, noninferiority study compares the safety and efficacy of the Compound Steep-Pulse Therapy Apparatus with radiofrequency ablation in adults with malignant liver tumors. Eligible participants are randomly assigned in a 1:1 ratio to the test group or the control group using a web-based central randomization system, with stratification by tumor diameter and tumor type. The primary outcome is the ablation success rate at 1 month after treatment, assessed by contrast-enhanced computed tomography or magnetic resonance imaging under blinded conditions. Secondary outcomes include ablation success at 3 months, complete ablation rates, tumor response, local recurrence-free rates, procedure-related complications, console operability, and system stability. Safety is evaluated through adverse events and laboratory assessments.

Eligibility Criteria

Inclusion Criteria: * 1.Age ≥18 and ≤80 years, regardless of sex. * 2.Diagnosed with a malignant liver tumor. * 3.Child-Pugh class A or B liver function. * 4.A single tumor ≤4 cm in diameter, or up to three tumor lesions, each with a maximum diameter ≤3 cm. * 5.Willing to participate in the study and voluntarily provide written informed consent. * 6.Expected survival \>6 months. Exclusion Criteria: * 1.Severe dysfunction of major organs, such as the heart, lungs, or kidneys, that, in the investigator's judgment, would preclude tolerance of treatment. * 2.Contraindications to general anesthesia. * 3.Allergy to contrast agents used for CT or MRI. * 4.Previous ablation of the target lesion. Newly developed lesions adjacent to a previously ablated target lesion may be eligible. * 5.Imaging evidence of invasion of major blood vessels or bile ducts on liver CT, MRI, or other imaging examinations. * 6.Severe coagulation abnormalities, defined as a platelet count \5 seconds. * 7.Uncorrectable refractory massive ascites or cachexia. * 8.Severe portal hypertension or a history of esophageal variceal bleeding within the past month. * 9.An implanted cardiac pacemaker or a metallic implant within 2.5 cm of the ablation zone. * 10.A history of epilepsy. * 11.A history of severe arrhythmia within the past month that could not be controlled with medication. * 12.Pregnancy, breastfeeding, or plans to conceive during the study. * 13.Participation in another drug or medical device trial without having exited that trial before enrollment. * 14.Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this clinical trial.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07916350). StuddyBuddy aggregates publicly available trial information.